company background image
VRTX

Vertex Pharmaceuticals NasdaqGS:VRTX Stock Report

Last Price

US$354.28

Market Cap

US$91.4b

7D

1.5%

1Y

25.0%

Updated

22 Sep, 2023

Data

Company Financials +

Vertex Pharmaceuticals Incorporated

NasdaqGS:VRTX Stock Report

Mkt Cap: US$91.4b

VRTX Stock Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).

VRTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Vertex Pharmaceuticals Incorporated Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vertex Pharmaceuticals
Historical stock prices
Current Share PriceUS$354.28
52 Week HighUS$367.00
52 Week LowUS$276.57
Beta0.51
1 Month Change1.05%
3 Month Change2.10%
1 Year Change24.99%
3 Year Change32.11%
5 Year Change83.81%
Change since IPO7,772.89%

Recent News & Updates

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jul 31
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

Recent updates

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jul 31
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Jul 03
We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued

Apr 30
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Apr 03
With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 24% Undervalued

Jan 23
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 24% Undervalued

If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Jan 02
If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 47%?

Oct 24
Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 47%?

Vertex to advance two AAT correctors to potentially treat rare, genetic disease

Oct 11

Do Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings Warrant Your Attention?

Oct 02
Do Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings Warrant Your Attention?

Vertex in licensing agreement with MaxCyte to use platform for gene editing candidate

Sep 28

Vertex Pharmaceuticals: Clinical Data Supports A Favorable Long-Term Growth Outlook

Sep 19

Vertex wins FDA label expansion for cystic fibrosis drug to add younger children

Sep 02

Vertex: CF Monopoly, Looking To Expand

Aug 05

Vertex to run late-stage studies for pain therapy in 4Q 2022

Jul 22

Vertex announces ViaCyte acquisition to expand diabetes pipeline

Jul 11

Vertex says FDA lifted clinical hold on trial for stem cell-based diabetes therapy

Jul 05

Vertex: In A Class By Itself, Promising Pipeline Of Game-Changing Drugs

Jun 28

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 44% Undervalued

Jun 27
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 44% Undervalued

AbbVie's Failure Solidifies Vertex Pharmaceuticals' Cystic Fibrosis Leadership Position

Jun 06

Vertex: Q1 Results Solid, If Unspectacular, But Pipeline Progress Makes Bull Case

May 06

Vertex Stock: Priced At A Premium For Good Reason, Although A Dip May Be Coming

Apr 07

Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Intrinsic Value Is Potentially 87% Above Its Share Price

Mar 28
Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Intrinsic Value Is Potentially 87% Above Its Share Price

Vertex: More Opportunities Ahead

Mar 22

Why Vertex Is One Of The Best Biotech Stocks To Own

Jan 31

Vertex: Growth At An Acceptable Valuation

Jan 25

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 50% Below Their Intrinsic Value Estimate

Dec 27
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 50% Below Their Intrinsic Value Estimate

Vertex: Waiting For The Pipeline Success

Dec 21

Recent Pipeline Updates Show Vertex Is Not Just About Cystic Fibrosis

Dec 07

Reasons To Buy Vertex Below $200

Sep 29

Shareholder Returns

VRTXUS BiotechsUS Market
7D1.5%-0.5%-1.5%
1Y25.0%10.8%13.8%

Return vs Industry: VRTX exceeded the US Biotechs industry which returned 10.8% over the past year.

Return vs Market: VRTX exceeded the US Market which returned 13.8% over the past year.

Price Volatility

Is VRTX's price volatile compared to industry and market?
VRTX volatility
VRTX Average Weekly Movement2.5%
Biotechs Industry Average Movement9.0%
Market Average Movement5.6%
10% most volatile stocks in US Market14.3%
10% least volatile stocks in US Market2.5%

Stable Share Price: VRTX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: VRTX's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19894,800Reshma Kewalramanihttps://www.vrtx.com

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company’s pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial.

Vertex Pharmaceuticals Incorporated Fundamentals Summary

How do Vertex Pharmaceuticals's earnings and revenue compare to its market cap?
VRTX fundamental statistics
Market CapUS$91.44b
Earnings (TTM)US$3.36b
Revenue (TTM)US$9.51b

27.2x

P/E Ratio

9.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VRTX income statement (TTM)
RevenueUS$9.51b
Cost of RevenueUS$4.02b
Gross ProfitUS$5.49b
Other ExpensesUS$2.12b
EarningsUS$3.36b

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)13.04
Gross Margin57.75%
Net Profit Margin35.40%
Debt/Equity Ratio0%

How did VRTX perform over the long term?

See historical performance and comparison